Assenagon Asset Management S.A. Has $152.72 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Assenagon Asset Management S.A. lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 244,927 shares of the biopharmaceutical company’s stock after buying an additional 37,139 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Regeneron Pharmaceuticals were worth $152,722,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. WPG Advisers LLC raised its holdings in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the period. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $26,000. SHP Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $26,000. Titan Wealth CI Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $29,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $31,000. 83.31% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on REGN. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Finally, Leerink Partners reiterated a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $797.75.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $772.11 on Friday. The stock has a market capitalization of $81.63 billion, a price-to-earnings ratio of 19.08, a PEG ratio of 1.35 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11. The firm has a fifty day simple moving average of $653.89 and a 200 day simple moving average of $711.82. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the business earned $12.81 EPS. The company’s revenue was up 16.7% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 43.11 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Improving earnings estimates suggest analysts see potential upside for REGN, supporting the recent share-price recovery. Surging Earnings Estimates Signal Upside for Regeneron Stock
• Positive Sentiment: Guggenheim raised its price target on Regeneron to $1,030, indicating substantial potential appreciation from recent trading levels and reinforcing the bullish case. Guggenheim Increases Regeneron Price Target
• Neutral Sentiment: Citigroup increased its price target to $740. While the revision is positive, the target remains below recent trading levels, signaling a more cautious view than Guggenheim’s. Citigroup Raises Regeneron Price Target
• Negative Sentiment: Several law firms are soliciting investors to lead or participate in a securities class action alleging that Regeneron made misleading statements about the prospects of its Phase 3 Fianlimab-Libtayo study in advanced melanoma. The lawsuit follows the trial failure and an earlier sharp decline in REGN’s value; the allegations have not been proven. Regeneron Investor Class Action Alert
• Negative Sentiment: The legal notices set a September 14, 2026 deadline for investors seeking lead-plaintiff status, keeping the failed trial and potential disclosure-related liabilities in focus. SueWallSt Regeneron Class Action Deadline

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.